Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis

Research output: Contribution to journalArticle

Standard

Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. / Geddes, J; Freemantle, Nick; Harrison, P; Bebbington, P.

In: British Medical Journal, Vol. 321, No. 7273, 02.12.2000, p. 1371-6.

Research output: Contribution to journalArticle

Harvard

APA

Vancouver

Author

Bibtex

@article{e0967355cc1149f3bf2921dbf0d57a7c,
title = "Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis",
abstract = "OBJECTIVE: To develop an evidence base for recommendations on the use of atypical antipsychotics for patients with schizophrenia. DESIGN: Systematic overview and meta-regression analyses of randomised controlled trials, as a basis for formal development of guidelines. SUBJECTS: 12 649 patients in 52 randomised trials comparing atypical antipsychotics (amisulpride, clozapine, olanzapine, quetiapine, risperidone, and sertindole) with conventional antipsychotics (usually haloperidol or chlorpromazine) or alternative atypical antipsychotics. MAIN OUTCOME MEASURES: Overall symptom scores. Rate of drop out (as a proxy for tolerability) and of side effects, notably extrapyramidal side effects. RESULTS: For both symptom reduction and drop out, there was substantial heterogeneity between the results of trials, including those evaluating the same atypical antipsychotic and comparator drugs. Meta-regression suggested that dose of conventional antipsychotic explained the heterogeneity. When the dose was ",
author = "J Geddes and Nick Freemantle and P Harrison and P Bebbington",
year = "2000",
month = dec,
day = "2",
doi = "10.1136/bmj.321.7273.1371",
language = "English",
volume = "321",
pages = "1371--6",
journal = "British Medical Journal",
issn = "0959-8138",
publisher = "BMJ Publishing Group",
number = "7273",

}

RIS

TY - JOUR

T1 - Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis

AU - Geddes, J

AU - Freemantle, Nick

AU - Harrison, P

AU - Bebbington, P

PY - 2000/12/2

Y1 - 2000/12/2

N2 - OBJECTIVE: To develop an evidence base for recommendations on the use of atypical antipsychotics for patients with schizophrenia. DESIGN: Systematic overview and meta-regression analyses of randomised controlled trials, as a basis for formal development of guidelines. SUBJECTS: 12 649 patients in 52 randomised trials comparing atypical antipsychotics (amisulpride, clozapine, olanzapine, quetiapine, risperidone, and sertindole) with conventional antipsychotics (usually haloperidol or chlorpromazine) or alternative atypical antipsychotics. MAIN OUTCOME MEASURES: Overall symptom scores. Rate of drop out (as a proxy for tolerability) and of side effects, notably extrapyramidal side effects. RESULTS: For both symptom reduction and drop out, there was substantial heterogeneity between the results of trials, including those evaluating the same atypical antipsychotic and comparator drugs. Meta-regression suggested that dose of conventional antipsychotic explained the heterogeneity. When the dose was

AB - OBJECTIVE: To develop an evidence base for recommendations on the use of atypical antipsychotics for patients with schizophrenia. DESIGN: Systematic overview and meta-regression analyses of randomised controlled trials, as a basis for formal development of guidelines. SUBJECTS: 12 649 patients in 52 randomised trials comparing atypical antipsychotics (amisulpride, clozapine, olanzapine, quetiapine, risperidone, and sertindole) with conventional antipsychotics (usually haloperidol or chlorpromazine) or alternative atypical antipsychotics. MAIN OUTCOME MEASURES: Overall symptom scores. Rate of drop out (as a proxy for tolerability) and of side effects, notably extrapyramidal side effects. RESULTS: For both symptom reduction and drop out, there was substantial heterogeneity between the results of trials, including those evaluating the same atypical antipsychotic and comparator drugs. Meta-regression suggested that dose of conventional antipsychotic explained the heterogeneity. When the dose was

U2 - 10.1136/bmj.321.7273.1371

DO - 10.1136/bmj.321.7273.1371

M3 - Article

C2 - 11099280

VL - 321

SP - 1371

EP - 1376

JO - British Medical Journal

JF - British Medical Journal

SN - 0959-8138

IS - 7273

ER -